Highnoon Laboratories Limited has entered into a strategic partnership with Beximco Pharmaceuticals Limited, a leading pharmaceutical manufacturer based in Bangladesh. This alliance marks a significant milestone in Highnoon’s international expansion strategy, aimed at bringing advanced technologies therapies and novel dosage forms to the Pakistani market. Both companies are listed on the stock exchanges of their respective countries.

The Memorandum of Understanding (MoU) was signed at Beximco’s headquarters in Dhaka by Dr Adeel Abbas, the co-chairman and chief executive officer (CEO) of Highnoon Laboratories Limited andRabbur Reza, the chief operating officer (COO) of Beximco Pharmaceuticals Limited.

This partnership will focus on the distribution marketing and sales of specialised pharmaceutical products in Pakistan with an emphasis on respiratory diabetes and cardiovascular therapeutic segments. The collaboration is designed to strengthen Highnoon’s portfolio in these high-impact areas providing a competitive edge through innovative drug delivery systems and clinical advancements.

Highnoon is listed on the Pakistan Stock Exchange and has earned its reputation over four decades as a quality-driven innovation-focused company. With cGMP-compliant manufacturing capabilities and a diverse product portfolio across major therapeutic areas Highnoon continues to position itself as a trusted healthcare partner both locally and internationally.

This collaboration also reflects the strengthening economic ties between Pakistan and Bangladesh reinforcing a shared vision for regional cooperation in healthcare and trade.

This content is an advertisement by Highnoon Laboratories Limited and is not associated with or necessarily reflective of the views of Dawn.com or its editorial staff.